Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics

References

• Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis 2000;30: 146–51.
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129–40.
   PubMed Web of Science ®Google Scholar
• Sádaba B, Azanza JR, Campanero MA, García-Quetglas E. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect 2004;10:990–8.
   PubMed Web of Science ®Google Scholar
• Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, . Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2304–8.
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484–9.
   PubMed Web of Science ®Google Scholar
• Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F, . Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936–7.
   PubMed Web of Science ®Google Scholar
• Beer R, Engelhardt KW, Pfausler B, Broessner G. Helbok R, Lackner P, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007;51:379–82.
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis. Ann Pharmacother 2006;40:1451–5.
   PubMed Web of Science ®Google Scholar
• Myrianthefs P, Markantonis SL, Vlachos K, Anagnostaki M, Boutzouka E, Panidis D, . Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006;50: 3971–6.
   PubMed Web of Science ®Google Scholar
• Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375–9.
   PubMedGoogle Scholar
• Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001;20:432–4.
   PubMed Web of Science ®Google Scholar
• Buerger C, Joukhadar C, Muller M, Kloft C. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:155–64.
   PubMed Web of Science ®Google Scholar
• Malacarne P, Viaggi B, Di Paolo A, Danesi R, Del Tacca M. Linezolid cerebrospinal fluid concentration in central nervous system infection. J Chemother 2007;19:90–3.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47:548–53.
   PubMed Web of Science ®Google Scholar
• Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008;31:122–9.
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008;62:416–26.
   PubMed Web of Science ®Google Scholar
• Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C, . Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005;55:333–40.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, . Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529–33.
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Rayner CR, Nation RL. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 2007;51:1287–92.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 2010;49:439–47.
   PubMed Web of Science ®Google Scholar
• Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use program. Clin Pharmacokinet 2003;42:1411–23.
   PubMed Web of Science ®Google Scholar
• Egle H, Trittler R, Kummerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005;77:451–3.
   PubMed Web of Science ®Google Scholar
• Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, . Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009;63:553–9.
   PubMed Web of Science ®Google Scholar
• Polillo M, Tascini C, Lastella M, Malacarne P, Ciofi L, Viaggi B, . A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 2010;32: 200–5.
   PubMed Web of Science ®Google Scholar